What Clinicians Want to Know: Addressing Current Questions and Controversies in the Care of Patients with Ovarian Cancer (OC)

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Care of Patients with Ovarian Cancer (OC) is organized by Research To Practice (RTP) and will be held on Mar 16, 2025 at Seattle Convention Center | Arch, Seattle, Washington, United States of America.

Learning Objectives
Upon completion of this activity, participants should be able to

• Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced OC, and as appropriate, counsel patients regarding personalized treatment recommendations.
• Assess available clinical trial data with and newly adapted indications for FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiregimen-refractory OC to optimally and appropriately incorporate these agents into management algorithms.
• Evaluate the biological rationale for and published research data with PARP inhibitors in combination with other systemic therapies, and consider the current and future clinical and research implications of these findings on OC management.
• Appraise relevant biological and patient- and treatment-related factors to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
• Recognize the rationale for targeting folate receptor alpha (FR?) in OC, and determine effective methods to test for this newly relevant biomarker.
• Understand the mechanism of action of and current research findings with antibody-drug conjugates directed at FR?, and optimally integrate these agents into the care of patients with recurrent OC.
• Appreciate side effects associated with various systemic therapies commonly employed in the management of OC, and use this information to develop supportive care plans for patients undergoing treatment with these agents.
• Recall the design of ongoing clinical trials evaluating novel agents and strategies for OC, and as appropriate, counsel patients about availability and participation.